Woman Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Phase 1B: To assess the tolerability of PF-04691502 combined with letrozole in postmenopausal patients with ER positive, HER 2 negative advanced breast cancer. Phase 2: To compare the change in Ki-67 value from baseline to Week 6 in matched tumor biopsies from patients with ER positive, HER-2 negative early breast cancer treated with PF-04691502 in combination with letrozole or letrozole alone.
Inclusion criteria
- ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER WITH KI-67 HIGHER THAN 10% AND ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE ADVANCED BREAST CANCER